Vaxcyte ($PCVX): Can Shares Reach the $110 Target After the +50% Move on VAX-31 Data? (Check any stock’s price target on Tickeron.) The $110 central target is the arithmetic mean of the verified analyst price targets reviewed, not a single firm's forecast. Following positive OPUS-1 Phase 3 data for VAX-31, shares jumped to a new 52-week high around $87–$89, requiring roughly a 26% gain to reach $110. The analyst range is unusually wide, from about $67 to $163, reflecting divergent views on market share, approval timing, and dilution. The strongest support comes from best-in-class VAX-31 immunogenicity data and a large, growing pneumococcal vaccine market. The biggest risks are execution, a lengthy timeline to commercialization (BLA filing targeted for the first half of 2028), competition, and a rich valuation with no current revenue. $BCYC $SRRK $DNLI $VIR $MIRM